What is a primary therapeutic benefit of long-acting fluphenazine decanoate given intramuscularly?

What is a primary therapeutic benefit of long-acting fluphenazine decanoate given intramuscularly?

• A. Prevent more extrapyramidal side effects
• B. Maintain long-term medication compliance
• C. Minimize side effects from benztropine
• D. Prevent risk of cardiac or renal disease

Answer: (B)

Long-acting injectable antipsychotics are focused on solving the big adherence challenge in schizophrenia. Fluphenazine decanoate, given intramuscularly, is released slowly over weeks, so the patient doesn’t need to take a pill every day. This steady delivery keeps medication levels in a therapeutic range and reduces the likelihood of relapse that often comes from missed oral doses. The primary benefit, therefore, is improved long-term medication compliance and ongoing symptom control. The injection doesn’t inherently prevent extrapyramidal symptoms or automatically protect against cardiac or renal risk; those are separate considerations tied to the drug’s pharmacology and the patient’s overall health.

Long-acting injectable antipsychotics are focused on solving the big adherence challenge in schizophrenia. Fluphenazine decanoate, given intramuscularly, is released slowly over weeks, so the patient doesn’t need to take a pill every day. This steady delivery keeps medication levels in a therapeutic range and reduces the likelihood of relapse that often comes from missed oral doses. The primary benefit, therefore, is improved long-term medication compliance and ongoing symptom control. The injection doesn’t inherently prevent extrapyramidal symptoms or automatically protect against cardiac or renal risk; those are separate considerations tied to the drug’s pharmacology and the patient’s overall health.